From: Breast Cancer Treatment (PDQ®)
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
TNM | Grade | HER2 Status | ER Status | PR Status | Stage Group |
---|---|---|---|---|---|
Tis, N0, M0 | Any (refer to Table 6 and Table 7) | Any | Any | Any | 0 |
T1b, N0, M0 | G1 | Positive | Positive | Positive | IA |
Negative | IA | ||||
T0, N1mi, M0 | Negative | Positive | IA | ||
Negative | IA | ||||
T1b, N1mi, M0 | Negative | Positive | Positive | IA | |
Negative | IA | ||||
Negative | Positive | IA | |||
Negative | IB | ||||
G2 | Positive | Positive | Positive | IA | |
Negative | IA | ||||
Negative | Positive | IA | |||
Negative | IA | ||||
Negative | Positive | Positive | IA | ||
Negative | IA | ||||
Negative | Positive | IA | |||
Negative | IB | ||||
G3 | Positive | Positive | Positive | IA | |
Negative | IA | ||||
Negative | Positive | IA | |||
Negative | IA | ||||
Negative | Positive | Positive | IA | ||
Negative | IB | ||||
Negative | Positive | IB | |||
Negative | IB | ||||
T0, N1c, M0; T1b, N1c, M0; T2, N0, M0 | G1 | Positive | Positive | Positive | IB |
Negative | IIA | ||||
Negative | Positive | IIA | |||
Negative | IIA | ||||
Negative | Positive | Positive | IB | ||
Negative | IIA | ||||
Negative | Positive | IIA | |||
Negative | IIA | ||||
G2 | Positive | Positive | Positive | IB | |
Negative | IIA | ||||
Negative | Positive | IIA | |||
Negative | IIA | ||||
Negative | Positive | Positive | IB | ||
Negative | IIA | ||||
Negative | Positive | IIA | |||
Negative | IIB | ||||
G3 | Positive | Positive | Positive | IB | |
Negative | IIA | ||||
Negative | Positive | IIA | |||
Negative | IIA | ||||
Negative | Positive | Positive | IIA | ||
Negative | IIB | ||||
Negative | Positive | IIB | |||
Negative | IIB | ||||
T2, N1d, M0; T3, N0, M0 | G1 | Positive | Positive | Positive | IB |
Negative | IIA | ||||
Negative | Positive | IIA | |||
Negative | IIB | ||||
Negative | Positive | Positive | IIA | ||
Negative | IIB | ||||
Negative | Positive | IIB | |||
Negative | IIB | ||||
G2 | Positive | Positive | Positive | IB | |
Negative | IIA | ||||
Negative | Positive | IIA | |||
Negative | IIB | ||||
Negative | Positive | Positive | IIA | ||
Negative | IIB | ||||
Negative | Positive | IIB | |||
Negative | IIIB | ||||
G3 | Positive | Positive | Positive | IB | |
Negative | IIB | ||||
Negative | Positive | IIB | |||
Negative | IIB | ||||
Negative | Positive | Positive | IIB | ||
Negative | IIIA | ||||
Negative | Positive | IIIA | |||
Negative | IIIB | ||||
T0, N2, M0; T1b, N2, M0; T2, N2, M0; T3, N1d, M0; T3, N2, M0 | G1 | Positive | Positive | Positive | IIA |
Negative | IIIA | ||||
Negative | Positive | IIIA | |||
Negative | IIIA | ||||
Negative | Positive | Positive | IIA | ||
Negative | IIIA | ||||
Negative | Positive | IIIA | |||
Negative | IIIB | ||||
G2 | Positive | Positive | Positive | IIA | |
Negative | IIIA | ||||
Negative | Positive | IIIA | |||
Negative | IIIA | ||||
Negative | Positive | Positive | IIA | ||
Negative | IIIA | ||||
Negative | Positive | IIIA | |||
Negative | IIIB | ||||
G3 | Positive | Positive | Positive | IIB | |
Negative | IIIA | ||||
Negative | Positive | IIIA | |||
Negative | IIIA | ||||
Negative | Positive | Positive | IIIA | ||
Negative | IIIB | ||||
Negative | Positive | IIIB | |||
Negative | IIIC | ||||
T4, N0, M0; T4, N1d, M0; T4, N2, M0; Any T, N3, M0 | G1 | Positive | Positive | Positive | IIIA |
Negative | IIIB | ||||
Negative | Positive | IIIB | |||
Negative | IIIB | ||||
Negative | Positive | Positive | IIIB | ||
Negative | IIIB | ||||
Negative | Positive | IIIB | |||
Negative | IIIC | ||||
G2 | Positive | Positive | Positive | IIIA | |
Negative | IIIB | ||||
Negative | Positive | IIIB | |||
Negative | IIIB | ||||
Negative | Positive | Positive | IIIB | ||
Negative | IIIB | ||||
Negative | Positive | IIIB | |||
Negative | IIIC | ||||
G3 | Positive | Positive | Positive | IIIB | |
Negative | IIIB | ||||
Negative | Positive | IIIB | |||
Negative | IIIB | ||||
Negative | Positive | Positive | IIIB | ||
Negative | IIIC | ||||
Negative | Positive | IIIC | |||
Negative | IIIC | ||||
Any T, Any N, M1 | Any (refer to Table 6 and Table 7) | Any | Any | Any | IV |
T = primary tumor; N = regional lymph node; M = distant metastasis.
aAdapted with permission from AJCC: Breast, revised version. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 4–96.
bT1 includes T1mi.
cN1 does not include N1mi. T1, N1mi, M0, and T0, N1mi, M0 cancers are included for prognostic staging with T1, N0, M0 cancers of the same prognostic factor status.
dN1 includes N1mi. T2, T3, and T4 cancers and N1mi are included for prognostic staging with T2, N1; T3, N1; and T4, N1, respectively.
Notes:
1. Because N1mi categorization requires evaluation of the entire node, and cannot be assigned on the basis of an fine-needle aspiration or core biopsy, N1mi can only be used with Clinical Prognostic Staging when clinical staging is based on a resected lymph node in the absence of resection of the primary cancer, such as in the situation where sentinel node biopsy is performed before receiving neoadjuvant chemotherapy or endocrine therapy.
2. For cases with lymph node involvement with no evidence of primary tumor (e.g., T0, N1, etc.) or with breast ductal carcinoma in situ (e.g.,Tis, N1, etc.), the grade, human epidermal growth factor receptor 2 (HER2), estrogen receptor, and progesterone receptor information from the tumor in the lymph node should be used for assigning stage group.
3. For cases where HER2 is determined to be equivocal by in situ hybridization (fluorescence in situ hybridization or chromogenic in situ hybridization) testing under the 2013 American Society of Clinical Oncologists/College of American Pathologists HER2 testing guidelines, the HER2-negative category should be used for staging in the Pathological Prognostic Stage Group table.[4,5]
4. The prognostic value of these Prognostic Stage Groups is based on populations of persons with breast cancer that have been offered and mostly treated with appropriate endocrine and/or systemic chemotherapy (including anti–HER2 therapy).
From: Breast Cancer Treatment (PDQ®)
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.